Analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to post sales of $3.02 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Voyager Therapeutics’ earnings, with estimates ranging from $2.00 million to $5.00 million. Voyager Therapeutics reported sales of $1.15 million in the same quarter last year, which indicates a positive year-over-year growth rate of 162.6%. The company is scheduled to report its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Voyager Therapeutics will report full-year sales of $19.07 million for the current year, with estimates ranging from $4.10 million to $80.15 million. For the next year, analysts expect that the business will post sales of $23.12 million, with estimates ranging from $4.60 million to $68.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. The business had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.00 million.
In other news, Director Glenn Pierce purchased 5,000 shares of the business’s stock in a transaction dated Wednesday, September 12th. The shares were acquired at an average price of $18.44 per share, for a total transaction of $92,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James A. Geraghty purchased 3,000 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were purchased at an average price of $19.39 per share, for a total transaction of $58,170.00. Following the acquisition, the director now directly owns 76,588 shares of the company’s stock, valued at $1,485,041.32. The disclosure for this purchase can be found here. Insiders have bought 11,000 shares of company stock worth $205,300 in the last 90 days. 33.60% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the company. BB Biotech AG raised its holdings in shares of Voyager Therapeutics by 27.1% during the second quarter. BB Biotech AG now owns 2,532,641 shares of the company’s stock valued at $49,488,000 after acquiring an additional 540,000 shares during the period. BlackRock Inc. raised its holdings in shares of Voyager Therapeutics by 28.3% during the second quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock valued at $36,066,000 after acquiring an additional 407,677 shares during the period. Millennium Management LLC raised its holdings in shares of Voyager Therapeutics by 124.0% during the first quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock valued at $11,613,000 after acquiring an additional 342,148 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Voyager Therapeutics by 15.2% during the second quarter. Wells Fargo & Company MN now owns 450,480 shares of the company’s stock valued at $8,802,000 after acquiring an additional 59,497 shares during the period. Finally, Laurion Capital Management LP raised its holdings in shares of Voyager Therapeutics by 23.2% during the second quarter. Laurion Capital Management LP now owns 355,950 shares of the company’s stock valued at $6,955,000 after acquiring an additional 66,987 shares during the period. Institutional investors and hedge funds own 89.64% of the company’s stock.
Shares of NASDAQ VYGR traded up $0.43 during midday trading on Monday, reaching $16.13. The company’s stock had a trading volume of 256,414 shares, compared to its average volume of 412,275. Voyager Therapeutics has a one year low of $11.54 and a one year high of $31.91. The company has a market capitalization of $613.69 million, a P/E ratio of -6.11 and a beta of 2.94.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Further Reading: Understanding Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.